{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:58:49Z","timestamp":1784602729706,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG6L0091-93,  CMRPG6P0091."],"award-info":[{"award-number":["CMRPG6L0091-93,  CMRPG6P0091."]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-024-01586-y","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T02:59:35Z","timestamp":1736218775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association between cytokines and progression-free survival in ovarian cancer following CRS\/HIPEC treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Chao-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Che","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hui","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Pin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jrhau","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"1","key":"1586_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1586_CR2","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/bcr2096","volume":"10","author":"BM Nolen","year":"2008","unstructured":"Nolen BM, Marks JR, Ta\u2019san S, Rand A, Luong TM, Wang Y, et al. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008;10(3):R45.","journal-title":"Breast Cancer Res"},{"key":"1586_CR3","doi-asserted-by":"crossref","unstructured":"Zhang L, Liu W, Wang X, Wang X, Sun H. Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy. Oncol Lett. 2019;17(2):2365\u20132369.","DOI":"10.3892\/ol.2018.9842"},{"issue":"1","key":"1586_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13402-020-00554-0","volume":"44","author":"GY Park","year":"2021","unstructured":"Park GY, Pathak HB, Godwin AK, Kwon Y. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation. Cell Oncol (Dordr). 2021;44(1):77\u201392.","journal-title":"Cell Oncol (Dordr)"},{"issue":"13","key":"1586_CR5","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1245\/s10434-021-10193-w","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, et al. HIPEC Methodology and regimens: the need for an Expert Consensus. Ann Surg Oncol. 2021;28(13):9098\u2013113.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1586_CR6","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1586_CR7","doi-asserted-by":"publisher","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","volume":"7","author":"P Filis","year":"2022","unstructured":"Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO open. 2022;7(5):100586.","journal-title":"ESMO open"},{"issue":"11","key":"1586_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","volume":"158","author":"JY Lee","year":"2023","unstructured":"Lee JY, Lee YJ, Son JH, Kim S, Choi MC, Suh DH, et al. Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with Advanced-Stage Ovarian Cancer who had received Neoadjuvant Chemotherapy. JAMA Surg. 2023;158(11):1133\u201340.","journal-title":"JAMA Surg"},{"issue":"3","key":"1586_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/jso.27125","volume":"127","author":"A Ayhan","year":"2023","unstructured":"Ayhan A, Akilli H, Abasiyanik MA, Taskiran C. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: when, and for whom? J Surg Oncol. 2023;127(3):457\u201364.","journal-title":"J Surg Oncol"},{"key":"1586_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3389\/fimmu.2018.00663","volume":"9","author":"GP Leijte","year":"2018","unstructured":"Leijte GP, Custers H, Gerretsen J, Heijne A, Roth J, Vogl T, et al. Increased plasma levels of Danger-Associated molecular patterns are Associated with Immune suppression and postoperative infections in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Front Immunol. 2018;9:663.","journal-title":"Front Immunol"},{"issue":"1","key":"1586_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejcb.2011.02.001","volume":"91","author":"A Jolesch","year":"2012","unstructured":"Jolesch A, Elmer K, Bendz H, Issels RD, Noessner E. Hsp70, a messenger from hyperthermia for the immune system. Eur J Cell Biol. 2012;91(1):48\u201352.","journal-title":"Eur J Cell Biol"},{"issue":"3","key":"1586_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/02656736.2017.1337238","volume":"34","author":"TY Wang","year":"2018","unstructured":"Wang TY, Chen CY, Lu CH, Chen MC, Lee LW, Huang TH, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia. Int J Hyperth. 2018;34(3):328\u201335.","journal-title":"Int J Hyperth"},{"issue":"1","key":"1586_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7800-2-3","volume":"2","author":"RL Harmon","year":"2005","unstructured":"Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3.","journal-title":"Int Semin Surg Oncol"},{"issue":"1","key":"1586_CR14","doi-asserted-by":"publisher","first-page":"18503","DOI":"10.1038\/s41598-020-75536-1","volume":"10","author":"A Yabuno","year":"2020","unstructured":"Yabuno A, Matsushita H, Hamano T, Tan TZ, Shintani D, Fujieda N, et al. Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Sci Rep. 2020;10(1):18503.","journal-title":"Sci Rep"},{"key":"1586_CR15","doi-asserted-by":"publisher","first-page":"108522","DOI":"10.1016\/j.pharmthera.2023.108522","volume":"250","author":"SU Khan","year":"2023","unstructured":"Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250:108522.","journal-title":"Pharmacol Ther"},{"key":"1586_CR16","doi-asserted-by":"crossref","unstructured":"Singh S, Anshita D, Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598.","DOI":"10.1016\/j.intimp.2021.107598"},{"key":"1586_CR17","doi-asserted-by":"crossref","unstructured":"Liu W, Wang L, Zhang J, Cheng K, Zheng W, Ma Z. CC chemokine 2 promotes ovarian Cancer Progression through the MEK\/ERK\/MAP3K19 Signaling Pathway. Int J Mol Sci. 2023;24(13).","DOI":"10.3390\/ijms241310652"},{"issue":"1","key":"1586_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/imr.13230","volume":"320","author":"ZJ Bernstein","year":"2023","unstructured":"Bernstein ZJ, Shenoy A, Chen A, Heller NM, Spangler JB. Engineering the IL-4\/IL-13 axis for targeted immune modulation. Immunol Rev. 2023;320(1):29\u201357.","journal-title":"Immunol Rev"},{"issue":"8","key":"1586_CR19","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-06-1828","volume":"13","author":"AJ Lambeck","year":"2007","unstructured":"Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res. 2007;13(8):2385\u201391.","journal-title":"Clin Cancer Res"},{"key":"1586_CR20","doi-asserted-by":"crossref","unstructured":"Chen WC, Chang TC, Chou HH, Cheng MH, Hong JJ, Hsieh YS et al. Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy. Int J Mol Sci. 2023;24(11).","DOI":"10.3390\/ijms24119748"},{"issue":"10","key":"1586_CR21","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00345-014-1458-3","volume":"33","author":"TJ Arends","year":"2015","unstructured":"Arends TJ, Falke J, Lammers RJ, Somford DM, Hendriks JC, de Weijert MC, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411\u20137.","journal-title":"World J Urol"},{"issue":"suppl8","key":"1586_CR22","doi-asserted-by":"publisher","first-page":"viii51","DOI":"10.1093\/annonc\/mdx441","volume":"28","author":"S Pignata","year":"2017","unstructured":"Pignata S, Du Bois SCC, Harter A, Heitz P. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28(suppl8):viii51\u20136.","journal-title":"Ann Oncol"},{"key":"1586_CR23","doi-asserted-by":"publisher","first-page":"102074","DOI":"10.1016\/j.canep.2021.102074","volume":"76","author":"K Gaitskell","year":"2022","unstructured":"Gaitskell K, Hermon C, Barnes I, Pirie K, Floud S, Green J, et al. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK million women study. Cancer Epidemiol. 2022;76:102074.","journal-title":"Cancer Epidemiol"},{"issue":"8","key":"1586_CR24","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.4161\/cbt.6.8.4506","volume":"6","author":"DS Son","year":"2007","unstructured":"Son DS, Parl AK, Rice VM, Khabele D. Keratinocyte chemoattractant (KC)\/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther. 2007;6(8):1302\u201312.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"1586_CR25","first-page":"1238","volume":"41","author":"A Mlynska","year":"2019","unstructured":"Mlynska A, Salciuniene G, Zilionyte K, Garberyte S, Strioga M, Intaite B, et al. Chemokine profiling in serum from patients with ovarian cancer reveals candidate biomarkers for recurrence and immune infiltration. Oncol Rep. 2019;41(2):1238\u201352.","journal-title":"Oncol Rep"},{"issue":"3","key":"1586_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1081\/IMM-200067648","volume":"34","author":"A Nagarsekar","year":"2005","unstructured":"Nagarsekar A, Hasday JD, Singh IS. CXC chemokines: a new family of heat-shock proteins? Immunol Invest. 2005;34(3):381\u201398.","journal-title":"Immunol Invest"},{"issue":"1","key":"1586_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/02656736.2019.1699172","volume":"36","author":"WC Huang","year":"2019","unstructured":"Huang WC, Wu CC, Hsu YT, Chang CL. Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy. Int J Hyperth. 2019;36(1):1255\u201363.","journal-title":"Int J Hyperth"},{"issue":"3","key":"1586_CR28","first-page":"310","volume":"82","author":"F Coccolini","year":"2016","unstructured":"Coccolini F, Corbella D, Finazzi P, Brambillasca P, Benigni A, Prussiani V, et al. Time course of cytokines, hemodynamic and metabolic parameters during hyperthermic intraperitoneal chemotherapy. Minerva Anestesiol. 2016;82(3):310\u20139.","journal-title":"Minerva Anestesiol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-024-01586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:02:34Z","timestamp":1764014554000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-024-01586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1186\/s13048-024-01586-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the funding section was corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}